Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and... Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private…